GI Innovation announced on April 3 that Phase 1 data for its immuno-oncology drug, GI-101A, has been selected for a rapid oral abstract presentation at the American Society of Clinical Oncology (ASCO 2026), the world’s most prestigious cancer conference.
ASCO is the most authoritative academic conference in the oncology field, where the latest clinical data is shared first. The conference evaluates the clinical value of new drugs based on real patient data. ASCO 2026 will be held in Chicago from May 29 to June 3.
GI Innovation plans to present the Phase 1 data for GI-101A at the conference. This oral presentation is part of a session that selects only top research from thousands of abstracts submitted worldwide, officially demonstrating the study’s competitiveness and impact in the global oncology community.
Chief Executive Officer (CEO) Jang Myung-ho stated that the selection of GI-101A for an oral presentation at ASCO is a recognition of its clinical potential and academic value by a prestigious conference. He added that through this presentation, it will clearly demonstrate the clinical significance of GI-101A and its strategic value as a combination therapy.